Preparation of liposomal vancomycin and intracellular killing of meticillin-resistant Staphylococcus aureus (MRSA)

Area of Science:

• Infectious Diseases
• Pharmacology
• Nanotechnology

Background:

• Meticillin-resistant Staphylococcus aureus (MRSA) infections, particularly pneumonia, pose a significant clinical challenge.
• Intracellular persistence of MRSA within alveolar macrophages contributes to treatment failures with standard intravenous vancomycin.
• Effective eradication of intracellular MRSA is crucial for successful pneumonia treatment.

Purpose of the Study:

• To evaluate the efficacy of liposomal vancomycin formulations against intracellular MRSA within macrophages.
• To compare the activity of non-pegylated and pegylated liposomal vancomycin against intracellular MRSA.
• To explore the potential of liposomal vancomycin as an improved therapeutic strategy for MRSA pneumonia.

Main Methods:

• Macrophages infected with MRSA were treated with standard vancomycin, non-pegylated liposomal vancomycin, and pegylated liposomal vancomycin.
• Liposomal formulations were prepared using a hydration-dehydration method.
• Intracellular MRSA viability was assessed after treatment with different vancomycin formulations.

Main Results:

• Standard vancomycin failed to eliminate intracellular MRSA.
• Non-pegylated liposomal vancomycin demonstrated significant bactericidal activity against intracellular MRSA.
• Pegylated liposomal vancomycin showed no impact on MRSA survival, likely due to delayed phagocytosis.

Conclusions:

• Conventional liposomal vancomycin can effectively target and kill intracellular MRSA within macrophages.
• Surface pegylation of liposomes may hinder their therapeutic efficacy against intracellular pathogens.
• Novel liposomal vancomycin delivery systems hold potential for improving treatment outcomes in MRSA pneumonia.